CYTX - Cytori Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4314
+0.0017 (+0.40%)
At close: 4:00PM EDT

0.4480 +0.02 (3.85%)
After hours: 7:23PM EDT

Stock chart is not supported by your current browser
Previous Close0.4297
Open0.4204
Bid0.4200 x 1300
Ask0.4480 x 1100
Day's Range0.4100 - 0.4380
52 Week Range0.3200 - 8.7000
Volume231,333
Avg. Volume772,487
Market Cap3.325M
Beta1.25
PE Ratio (TTM)N/A
EPS (TTM)-4.2830
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
Trade prices are not sourced from all markets
  • Cytori's Chemotherapy Candidate Gets Orphan Drug Status
    Zacks7 days ago

    Cytori's Chemotherapy Candidate Gets Orphan Drug Status

    Cytori Therapeutics' (CYTX) chemotherapy candidate, ATI-1123, gets orphan drug status from the FDA for small cell lung cancer.

  • GlobeNewswire8 days ago

    Phase 2 Ready Oncology Drug Receives FDA Orphan Drug Designation

    The FDA’s Orphan Drug Designation Program provides orphan status to drugs, such as ATI-1123, which are intended for the safe and effective treatment of rare diseases/disorders that affect fewer than 200,000 people in the U.S.  Sponsors of a drug receiving orphan designation qualify for various incentives including tax credits for clinical testing, 7 years of marketing exclusivity following FDA approval, and a waiver of prescription drug user fees. Small cell lung cancer (SCLC), which accounts for approximately 15% of bronchogenic carcinomas with 33,375 new cases and 23,380 deaths estimated for 2017, has been identified by Cytori as a compelling target for ATI-1123.  While SCLC is responsive to chemotherapy and radiation therapy, cure occurs only in ~20% of patients, generally restricted to those with limited stage disease.  The remaining 80% of patients, including all patients with extensive disease, relapse within months of completing their initial therapy.

  • Thomson Reuters StreetEvents25 days ago

    Edited Transcript of CYTX earnings conference call or presentation 14-Aug-18 9:30pm GMT

    Q2 2018 Cytori Therapeutics Inc Earnings Call

  • GlobeNewswire25 days ago

    Cytori Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

    SAN DIEGO, Aug. 31, 2018-- Cytori Therapeutics, Inc. announced today that it will present at the 20 th Annual Rodman & Renshaw Global Investment Conference at 09:10 AM Eastern Time on Thursday, September ...

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Medtronic and Cytori Therapeutics

    NEW YORK, NY / ACCESSWIRE / August 22, 2018 / Medtronic shares hit a brand new high after announcing impressive first quarter results. Shares of Cytori Therapeutics also soared in Tuesday’s session despite ...

  • Benzingalast month

    The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

    Here's a roundup of top developments in the biotech space over the last 24 hours.  Scaling the Peaks (Stocks hitting 52-week highs on Aug. 15) Inspire Medical Systems Inc (NYSE: INSP ) Merck & Co., Inc. ...

  • Benzingalast month

    The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 14) DexCom, Inc. (NASDAQ: DXCM ) Masimo Corporation (NASDAQ: MASI ...

  • Associated Presslast month

    Cytori: 2Q Earnings Snapshot

    The San Diego-based company said it had a loss of 59 cents per share. The developer of cell therapies posted revenue of $1.6 million in the period. In the final minutes of trading on Tuesday, the company's ...

  • GlobeNewswirelast month

    Cytori Reports Q2 2018 Business and Financial Results

    SAN DIEGO, Aug. 14, 2018-- Cytori Therapeutics today announced Q2 2018 financial results and provided updates on corporate activities. Q2 2018 net loss was $3.7 million, or $0.59 per share. Operating cash ...

  • Benzingalast month

    The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 13) Iradimed Corp (NASDAQ: IRMD ) SurModics, Inc. (NASDAQ: SRDX ...

  • GlobeNewswire2 months ago

    Cytori Reports Publication of Interim Pilot Data for Cell Therapy in Vocal Fold Scarring

    SAN DIEGO, Aug. 09, 2018-- Cytori Therapeutics, Inc. announced publication in the peer-reviewed journal, Stem Cell Research and Therapy, of“ Autologous adipose-derived stromal vascular fraction and scarred ...

  • GlobeNewswire2 months ago

    Cytori to Webcast Second Quarter Financial Results on August 14

    Cytori Therapeutics, Inc. (CYTX) will provide a live webcast of its second quarter financial results and business update on Tuesday, August 14, 2018 at 5:30 PM Eastern Time. Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties.

  • GlobeNewswire2 months ago

    Cytori Announces $6.7 Million in Expected Gross Proceeds from Recently Expired Rights Offering

    Cytori Therapeutics, Inc. (CYTX) announced today that its previously announced rights offering (“the Rights Offering”) expired on July 20, 2018 and such rights are no longer exercisable. Cytori accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $6.7 million in gross proceeds. The results of the Rights Offering and Cytori’s estimates regarding the aggregate gross proceeds of the Rights Offering to be received by Cytori are subject to finalization and verification by Cytori and its subscription agent.

  • GlobeNewswire2 months ago

    Cytori Reminds Stockholders That Rights Offering Expires on Friday, July 20

    Cytori Therapeutics, Inc. (CYTX) provides a reminder to stockholders that its previously announced rights offering will remain open until 5:00 PM Eastern Time on Friday, July 20, 2018. Rights holders will need to exercise their subscription rights prior to that date and time. The unit pricing remains $1,000 per unit, each unit consisting of one share of Series C Preferred Stock with a face value of $1,000 (and immediately convertible into common stock at a conversion price of the lesser of (a) $1.45 per share and (b) 85% of the lowest daily volume weighted average price for our common stock, as reported at the close of trading by Nasdaq, during the five trading days prior to the expiration of the rights offering (including the expiration date), subject to adjustment) and 621 warrants.

  • GlobeNewswire3 months ago

    Cytori Reports Sustained Benefit of Cell Therapy in Erectile Dysfunction Trial

    SAN DIEGO, July 09, 2018-- Cytori Therapeutics, Inc. announced publication in the peer-reviewed journal, Urology, of“ A 12- Month Follow-up After a Single Intracavernous Injection of Autologous Adipose-derived ...

  • GlobeNewswire3 months ago

    Cytori Reports Improved Skin Healing in Pivotal Burn Preclinical Study

    Cytori Therapeutics, Inc. (CYTX) announced today the publication of preclinical data from a study using intravenous delivery of Cytori Cell Therapy™ in a model of large burn injury representative of patients being recruited in the ongoing RELIEF clinical trial. This study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA) as a component of the preclinical data supporting the FDA approved United States RELIEF Trial. In the study described in this publication, Adipose Derived Regenerative Cells (ADRCs), the active component of Cytori Cell Therapy™, were delivered by intravenous injection in a porcine model of mixed full-and partial thickness burn injury covering approximately 20% of total body surface area in which full thickness burns were treated with a meshed autologous split-thickness skin graft.

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 26) AngioDynamics, Inc. (NASDAQ: ANGO ) Chembio Diagnostics Inc ...

  • Cytori Therapeutics Inc (NASDAQ:CYTX): Are Analysts Optimistic?
    Simply Wall St.4 months ago

    Cytori Therapeutics Inc (NASDAQ:CYTX): Are Analysts Optimistic?

    Cytori Therapeutics Inc’s (NASDAQ:CYTX): Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medicalRead More...

  • Benzinga4 months ago

    Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 23) ABIOMED, Inc. (NASDAQ: ABMD ) ArQule, Inc. (NASDAQ: ARQL ) Crispr ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CYTX earnings conference call or presentation 10-May-18 9:30pm GMT

    Q1 2018 Cytori Therapeutics Inc Earnings Call

  • Business Wire4 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cytori Therapeutics, Inc.

    Levi & Korsinsky announces it has commenced an investigation of Cytori Therapeutics, Inc. concerning possible breaches of fiduciary duty. To obtain additional

  • Associated Press5 months ago

    Cytori: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 7 cents. The developer of cell therapies posted revenue of $731,000 in the period. In the final minutes of trading on Thursday, the ...